Kalaris Therapeutics, Inc. Common Stock KLRS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$10.86M-6.5% | -$10M+54.6% | -$11.89M+68.8% | -$11.35M-101% | -$10.2M-199% | ||
| $10K— | $10K— | —— | —— | —— | ||
| $580K+55.1% | $333K+18.9% | $638K+144% | $591K+83.5% | $374K+1,106% | ||
| -$11.58M-55.6% | -$7.06M+10.1% | -$11.33M-162% | -$12.54M-216% | -$7.44M-64.6% | ||
| -$50.35M-921% | -$4.93M-199% | -$4.93M-125% | -$4.93M-116% | -$4.93M-112% | ||
| -$1.7M-102% | $47.74M+530% | —— | —— | $107.27M+1,530% | ||
| -$63.63M-164% | $55.67M+20,416% | —— | —— | $99.83M+4,751% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kalaris Therapeutics, Inc. Common Stock generate?
- Kalaris Therapeutics, Inc. Common Stock (KLRS) generated -$42.5M in operating cash flow over the trailing twelve months.
- What is Kalaris Therapeutics, Inc. Common Stock's free cash flow?
- After $36.5K of capital expenditures, Kalaris Therapeutics, Inc. Common Stock's free cash flow was -$86.8M over the trailing twelve months.
- Where does Kalaris Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.